Vertex Historical Cash Flow
| VRTX Stock | USD 481.38 1.03 0.21% |
Analysis of Vertex Pharmaceuticals cash flow over time is an excellent tool to project Vertex Pharmaceuticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 10.9 B or Other Cashflows From Financing Activities of 92.9 M as it is a great indicator of Vertex Pharmaceuticals ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Vertex Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Vertex Pharmaceuticals is a good buy for the upcoming year.
Vertex |
About Vertex Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Vertex balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Vertex's non-liquid assets can be easily converted into cash.
Vertex Pharmaceuticals Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Depreciation
Depreciation indicates how much of Vertex Pharmaceuticals value has been used up. For tax purposes Vertex Pharmaceuticals can deduct the cost of the tangible assets it purchases as business expenses. However, Vertex Pharmaceuticals must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Total Cashflows From Investing Activities
The net amount of cash used in or generated from a company's investment activities, such as purchasing or selling assets, during a reporting period.Most accounts from Vertex Pharmaceuticals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Vertex Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.At this time, Vertex Pharmaceuticals' Begin Period Cash Flow is fairly stable compared to the past year. Depreciation is likely to rise to about 217.6 M in 2025, despite the fact that Change In Cash is likely to grow to (5.5 B).
| 2022 | 2023 | 2024 | 2025 (projected) | Capital Expenditures | 204.7M | 258.4M | 297.7M | 312.6M | Depreciation | 148.3M | 181.3M | 207.2M | 217.6M |
Vertex Pharmaceuticals cash flow statement Correlations
Click cells to compare fundamentals
Vertex Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Vertex Pharmaceuticals cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 2.9B | 811.2M | 3.7B | (139.7M) | (5.8B) | (5.5B) | |
| Free Cash Flow | 3.0B | 2.4B | 3.9B | 3.3B | (790.3M) | (750.8M) | |
| Change In Working Capital | (54.5M) | (105.2M) | 340.8M | (265.7M) | (514.8M) | (489.1M) | |
| Begin Period Cash Flow | 3.1B | 6.0B | 6.8B | 10.5B | 10.4B | 10.9B | |
| Other Cashflows From Financing Activities | 276.4M | 130.3M | 186.3M | 134.6M | 120.8M | 92.9M | |
| Depreciation | 109.5M | 125.6M | 148.3M | 181.3M | 207.2M | 217.6M | |
| Capital Expenditures | 259.8M | 235M | 204.7M | 258.4M | 297.7M | 312.6M | |
| Total Cash From Operating Activities | 3.3B | 2.6B | 4.1B | 3.5B | (492.6M) | (468.0M) | |
| Net Income | 2.7B | 2.3B | 3.3B | 3.6B | (535.6M) | (508.8M) | |
| Total Cash From Financing Activities | (505.3M) | (1.5B) | (67.7M) | (562.2M) | (1.5B) | (1.4B) | |
| End Period Cash Flow | 6.0B | 6.8B | 10.5B | 10.4B | 4.6B | 4.8B | |
| Other Non Cash Items | (220.0M) | (5.8M) | 103.4M | (42.6M) | 900K | 855K | |
| Change To Liabilities | 188.1M | 598.6M | 354.1M | 1.2B | 1.3B | 1.4B | |
| Change To Account Receivables | (223.4M) | (274.7M) | (358.6M) | (84.1M) | (99.3M) | (104.3M) | |
| Stock Based Compensation | 429.5M | 441.4M | 491.3M | 581.2M | 698.5M | 733.4M | |
| Other Cashflows From Investing Activities | (19.3M) | (77M) | 179.5M | (58M) | (499.7M) | (474.7M) | |
| Change To Inventory | (132.0M) | (92.8M) | (136.4M) | (322.9M) | (517.3M) | (491.4M) | |
| Total Cashflows From Investing Activities | (1.2B) | 99.4M | (340.9M) | (321.1M) | (289.0M) | (274.5M) | |
| Sale Purchase Of Stock | (739.4M) | (1.6B) | (172M) | (653.7M) | (1.6B) | (1.5B) | |
| Dividends Paid | 20.8M | 10.0M | 264.9M | 102M | 117.3M | 123.2M | |
| Investments | 378.5M | (28.9M) | 227.3M | (2.1B) | (3.8B) | (3.6B) | |
| Change Receivables | (225.6M) | (223.4M) | (274.7M) | (358.6M) | (322.7M) | (306.6M) | |
| Net Borrowings | (35.0M) | (29.0M) | (24.4M) | (85.5M) | (77.0M) | (73.1M) | |
| Cash And Cash Equivalents Changes | 460.8M | 2.8B | 824.6M | 3.7B | 4.3B | 4.5B | |
| Cash Flows Other Operating | 5.2M | (332.2M) | (263.5M) | (453.2M) | (407.9M) | (387.5M) | |
| Change To Netincome | 381.9M | 521.4M | 452.7M | 445.6M | 512.4M | 437.4M | |
| Change To Operating Activities | 246.3M | 249.7M | 230.4M | 715M | 822.3M | 863.4M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Vertex Stock Analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.